Advanced in Paronychia

Yukio Hosomi

Komagome, JP 
Advanced in Paronychia
Komagome, JP 
OverviewLocationsClinical Research

Overview

Yukio Hosomi practices in Komagome, Japan. Mr. Hosomi is rated as an Advanced expert by MediFind in the treatment of Paronychia. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 157 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Paronychia.

Gender
Male

Locations

Komagome, Japan
Other Locations
Honkomagome, 1130021, Japan
Tokyo, Japan
Bunkyo, Japan
Komagome, Japan
Chiba, Japan
Maebashi, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2

157 Total Publications

Corrigendum to 'Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)' [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912-927].
Corrigendum to 'Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)' [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912-927].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hosomi's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile